FDA approves Orca Bio's T cell therapy Tregzi to lower transplant complications in blood cancer patients
The U.S. Food and Drug Administration has granted approval to Orca Bio's T cell therapy aimed at improving outcomes for patients undergoing blood cancer transplants.
The therapy, named Tregzi, is designed to reduce transplant-related complications by leveraging regulatory T cells to modulate immune responses.
Orca Bio's CEO Nate Fernhoff highlighted that the approval could provide a new option for clinicians to enhance transplant safety and efficacy.
The decision marks a significant milestone for the company's cell-based platform and may influence future development of similar immunotherapies.
This writeup was produced by pharmadog from original reporting by Endpoints.
Original headline: “FDA approves Orca Bio’s cell therapy to improve transplant outcomes”
read at Endpoints ↗
comments(0)
5-min edit window · permanent after that